Personalized CAR-T therapy for recurring brain tumor
Part of Brain & nervous system, Cancer clinical trials.
This Phase 1 study tests a personalized immune-cell treatment (CAR-T) made from your own cells to attack a marker called B7-H3 on recurring glioblastoma. It may help shrink or control the tumor, but the main goal is to check safety and how the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have glioblastoma that has come back or didn’t respond well to treatment, confirmed by recent brain scans
- You’ve had brain surgery (resection) or a biopsy at the time of diagnosis
- You are strong enough for study treatment (Karnofsky score above 60%)
- You’ve already had specific prior treatment: at least 4005 cGy radiation with chemotherapy called temozolomide
- You have not used certain anti-cancer blood-vessel medicines before (for example, bevacizumab)
- You can have repeat MRI scans (no allergy/medical issue with contrast and you have no MRI-incompatible implants)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a customized immune-cell treatment (CAR T cells) for adults with newly diagnosed glioblastoma (GBM) whose tumors have enough CD70 protein. If you qualify, the goal is to see whether this treatment can better control the cancer by targeting it in the brain.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests a new type of immunotherapy called CAR-T cells, made from donor cells, for people whose glioblastoma (a type of brain cancer) has come back after standard treatment. The goal is to see if it can shrink the tumor or slow its growth.
This trial tests a new CAR-T cell treatment (SNC-109) for people with glioblastoma that has come back after initial treatment. The therapy uses your own immune cells, modified in a lab, to try to attack the tumor.
This trial tests a new type of immune cell therapy (CAR-T cells) made from donor cells, designed to target tumors with a specific marker called CD70. It is for people whose brain glioma has come back or hasn't responded to standard treatments.
This early-phase study tests a type of immune-cell treatment (CAR T cells) aimed at a target called B7-H3 in people with glioblastoma or related grade 4 brain tumors that have come back. It’s meant to see if the treatment can shrink the tumor or control the disease and to learn how safe it is.
Hear when a new Glioblastoma Multiforme trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.